Industry News: Study Finds that Pancreatic Cancer Patient Survival Doubled with High Dose of Vitamin C
A recent study from the University of Iowa suggests that high-dose intravenous vitamin C, when combined with chemotherapy, may improve survival rates for patients with late-stage metastatic pancreatic cancer. In this phase 2 trial, patients receiving 75 grams of vitamin C three times a week alongside chemotherapy experienced an increase in overall survival from eight to sixteen months, and progression-free survival from four to six months.
The study suggests that high-dose vitamin C generates hydrogen peroxide, selectively targeting and killing cancer cells without harming normal tissue. Furthermore, patients undergoing this combination therapy exhibited better tolerance to chemotherapy, enabling longer and higher-dose treatment protocols. These findings highlight a potential adjunctive role for vitamin C in enhancing both therapeutic efficacy and patient outcomes.
While the results are encouraging, the researchers emphasize the need for larger randomized trials to validate these findings and establish clinical guidelines. Healthcare professionals considering this approach are advised to engage in informed discussions with patients and integrate this option judiciously within evidence-based oncology practices.
For more details on the study, read the complete article: Pancreatic Cancer Patient Survival Doubled with High Dose of Common Vitamin, Study Finds.
Disclaimer:
McGuff Pharmaceuticals, Inc. (MPI) provides this communication for the purpose of sharing scientific information with healthcare providers engaged in making clinical practice decisions for the care of individual patients. The information presented is reprinted from a publicly available news article, "Pancreatic cancer patient survival doubled with high dose of common vitamin, study finds," published by FOX News on December 4, 2024, written by Angelica Stabile. The article does not reference MPI’s FDA-approved product, Ascor® (Ascorbic Acid Injection), or any specific brand.
MPI provided financial and technical support for the referenced Phase II clinical trial, "High-Dose Ascorbate for Pancreatic Cancer (PACMAN 2’2)" (NCT02905578), led by Joseph J. Cullen, MD, FACS, at The University of Iowa. However, MPI was not involved in the design, implementation, analysis, or interpretation of the study protocol, data, or results.
This communication is not intended to promote unapproved uses of any product. Healthcare providers are encouraged to refer to the published scientific literature and consider the clinical context when making treatment decisions. For information about the approved indications for MPI’s products, please refer to the official prescribing information for Ascor®.
